Sage Therapeutics Inc. announced positive results from a phase 2 trial for an oral treatment that was linked to improvements in functioning, learning and memory in those with mild cognitive impairment from Parkinson’s disease.
Data on the first-in-class, positive allosteric modulator of the NMDA receptor, dubbed SAGE-718, were reported from the open label phase 2 PARADIGM study, part of the biopharmaceutical company’s early-stage trial platform to treat cognitive deficits across a range of brain disorders.
“Improving cognitive function is an area of significant unmet need in